Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Biopharmaceutical Factors Influencing Drug Product Design: Overview01:22

Biopharmaceutical Factors Influencing Drug Product Design: Overview

Rational drug product design integrates knowledge of the drug’s physicochemical properties, formulation components, manufacturing techniques, and intended route of administration. Each factor influences the drug’s performance, including how it is released, absorbed, and eliminated in the body.The physicochemical properties of a drug—such as solubility, stability, and particle size—affect its compatibility with excipients and the choice of dosage form. Excipients, though pharmacologically...
Clinically Relevant Drug Product Specifications: Methods of Establishment01:29

Clinically Relevant Drug Product Specifications: Methods of Establishment

Product specifications define the acceptable quality of a pharmaceutical product by ensuring identity, purity, potency, and strength. These specifications serve as benchmarks during development, manufacturing, and post-approval quality control. Clinically relevant specifications are particularly important because they directly relate to a drug's safety and efficacy in clinical use.Dissolution studies are critical biopharmaceutic tools that link in vitro behavior to in vivo performance. They...
Impact of Pharmacokinetic–Pharmacodynamic Models: Regulatory Decisions01:15

Impact of Pharmacokinetic–Pharmacodynamic Models: Regulatory Decisions

PK–PD modeling has significantly influenced FDA regulatory decisions, particularly drug approval, dosage optimization, and labeling. These models integrate pharmacokinetics (PK) and pharmacodynamics (PD) to predict drug behavior and effects, aiding in optimizing dosing regimens and enhancing the probability of clinical trial success.One notable example is Nesiritide (Natrecor®), a recombinant human brain natriuretic peptide for treating acute decompensated congestive heart failure (CHF).
Drug Dissolution: Requirements and Profile Comparison01:14

Drug Dissolution: Requirements and Profile Comparison

The acceptance criteria for dissolution profile data are anchored in Q values, representing the percentage of drug dissolved within a specified period. This assessment unfolds in three stages:First Stage: The test passes if all six drug dosage units are equal to or greater than Q plus 5%; otherwise, the sample proceeds to the second stage.Second Stage: The average of twelve units must be equal to or greater than Q, with no unit falling below Q - 15% to pass; if not, it progresses to the final...
Factors Influencing Drug Absorption: Pharmaceutical Parameters01:28

Factors Influencing Drug Absorption: Pharmaceutical Parameters

Solid dosage forms such as tablets and capsules undergo rigorous manufacturing processes to ensure stability and effectiveness. Their dissolution and absorption properties are influenced significantly by the choice of excipients (inactive ingredients that serve various roles in the formulation), and the methodology applied during production. The manufacturing parameters, such as compression force and granulation techniques, significantly affect dissolution rates. Elevated compression forces...
Formulation and Manufacturing Process: Physical Attributes of Generic Tablets and Capsules01:18

Formulation and Manufacturing Process: Physical Attributes of Generic Tablets and Capsules

Bioequivalence in generic drugs, such as tablets and capsules, refers to their pharmaceutical equivalence to the brand-name counterparts. However, for therapeutic equivalence, manufacturers must also consider physical attributes like size, shape, and weight (FDA Guidance for Industry, December 2003). Discrepancies in these aspects could impact patient compliance and cause medication errors. For instance, swallowing difficulties, often experienced with larger tablets or capsules, can lead to...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

An online brain-computer interface for detecting incongruity in augmented reality applications.

Journal of neural engineering·2026
Same journal

RETRACTED: Meligy et al. Therapeutic Potential of Mesenchymal Stem Cells Versus Omega n - 3 Polyunsaturated Fatty Acids on Gentamicin-Induced Cardiac Degeneration. <i>Pharmaceutics</i> 2022, <i>14</i>, 1322.

Pharmaceutics·2026
Same journal

Correction: Mohite et al. Bioactive Compound-Fortified Nanomedicine in the Modulation of Reactive Oxygen Species and Enhancement of the Wound Healing Process: A Review. <i>Pharmaceutics</i> 2025, <i>17</i>, 855.

Pharmaceutics·2026
Same journal

Metal Nanoparticle-Reinforced Hydrogels Applied in the Inhibition of Clinical Pathogens: Structural Features, Mechanisms, and Biomedical Prospects.

Pharmaceutics·2026
Same journal

Development and Evaluation of a Physiologically Based Pharmacokinetic Model for Cipepofol Across Diverse Clinical Populations.

Pharmaceutics·2026
Same journal

Artificial Intelligence in Nanopharmaceutical Development: From Predictive Design to Clinical Translation.

Pharmaceutics·2026
Same journal

Textilinin-1, a Snake Venom-Derived Kunitz-Type Protease Inhibitor, Accelerates Wound Healing Through Anti-Inflammatory, Antibacterial, and Pro-Regenerative Activities.

Pharmaceutics·2026
See all related articles

Related Experiment Video

Updated: Jun 27, 2026

Development of Inhibitors of Protein-protein Interactions through REPLACE: Application to the Design and Development Non-ATP Competitive CDK Inhibitors
10:33

Development of Inhibitors of Protein-protein Interactions through REPLACE: Application to the Design and Development Non-ATP Competitive CDK Inhibitors

Published on: October 26, 2015

An Interactive Constraint-Based Decision-Support Tool for Pharmaceutical Formulation Development.

Reihaneh Manteghi1,2, Eduardo Veas1,2

  • 1Institute of Human-Centred Computing, Graz University of Technology, Sandgasse 36, 3rd Floor, 8010 Graz, Austria.

Pharmaceutics
|June 26, 2026
PubMed
Summary
This summary is machine-generated.

A new interactive tool aids pharmaceutical formulation development by organizing knowledge and supporting decision-making for drug products. This system helps predict dosage forms and processing routes, improving efficiency in drug design.

Keywords:
constraint satisfaction problemdata-driven formulationdecision-support systemsinteractive visualizationpharmaceutical formulation

More Related Videos

A Bilingual Computational Workflow for Identifying Potential PLK1 Inhibitors in American Sign Language and English
14:34

A Bilingual Computational Workflow for Identifying Potential PLK1 Inhibitors in American Sign Language and English

Published on: April 3, 2026

Related Experiment Videos

Last Updated: Jun 27, 2026

Development of Inhibitors of Protein-protein Interactions through REPLACE: Application to the Design and Development Non-ATP Competitive CDK Inhibitors
10:33

Development of Inhibitors of Protein-protein Interactions through REPLACE: Application to the Design and Development Non-ATP Competitive CDK Inhibitors

Published on: October 26, 2015

A Bilingual Computational Workflow for Identifying Potential PLK1 Inhibitors in American Sign Language and English
14:34

A Bilingual Computational Workflow for Identifying Potential PLK1 Inhibitors in American Sign Language and English

Published on: April 3, 2026

Area of Science:

  • Pharmaceutical Science
  • Computational Chemistry
  • Drug Delivery Systems

Background:

  • Pharmaceutical formulation is complex, facing challenges with limited, proprietary data.
  • Interactive digital tools can enhance decision-making in early drug product development.
  • Current systems offer structured support, with potential for machine learning integration.

Purpose of the Study:

  • To develop an interactive decision-support and visualization system for pharmaceutical formulation.
  • To prioritize formulation principles and processing routes for oral solid and liquid dosage forms.
  • To evaluate the tool's practical applicability through an expert study.

Main Methods:

  • Developed the 'Formulation tool' based on a hierarchical formulation-strategy framework.
  • Applied a constraint satisfaction problem (CSP) framework for decision modeling.
  • Conducted an expert study with 5 users across 6 scenarios and 30 runs.

Main Results:

  • The tool demonstrated agreement with expected dosage-form families (oral solid for adults, oral liquid for pediatrics).
  • Users converged to expected or alternative feasible formulation pathways.
  • Median task completion time was 113.5 seconds, with variability linked to user interaction.

Conclusions:

  • The Formulation tool organizes knowledge and records user interactions for future learning.
  • The CSP framework effectively models complex pharmaceutical formulation decisions.
  • The tool supports structured decision-making in formulation strategy development.